|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
|
31522240 |
2020 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
Compounds PY3, PY2, and PY1 were identified as potential leads amongst the series, with promising anticancer activity against human breast cancer and melanoma cells, and the ability to inhibit Hsp90 similar to radicicol by drug-affinity responsive target stability proteomic analysis in a whole-cell assay.
|
31808979 |
2020 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
It regulates the stability and function of numerous client proteins that are frequently upregulated and/or mutated in cancer cells, therefore, making Hsp90 inhibition a promising therapeutic strategy for the development of new efficacious drugs to treat breast cancer.
|
31493740 |
2019 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
Together, we discovered that HSP90AB1 is USP22-dependent and that cooperative targeting of USP22 and HSP90 may provide an effective approach to the treatment of colorectal and breast cancer.
|
31801945 |
2019 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
Translocase of the outer mitochondrial membrane 34 (Tomm34) is a cochaperone of both Hsp70 and Hsp90 that was found to be overexpressed in colorectal, hepatocellular, lung and breast carcinomas.
|
30917858 |
2019 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
In conclusion, our findings, identifying for the first time leptin/leptin receptor/Hsp90 axis as an important regulator of exosome generation in mammary carcinoma cells, suggest that targeting this signaling pathway might represent a novel therapeutic strategy to impair exosome secretion and interrupt the dangerous cell-to-cell communication in breast cancer.
|
31336913 |
2019 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
We have developed a non-destructive strategy using HS-27, a fluorescently-tethered Hsp90 inhibitor, to assay surface Hsp90 expression on intact tissue specimens and validated our approach in clinical samples from breast cancer patients across estrogen receptor positive, Her2-overexpressing, and triple negative receptor subtypes.
|
30837677 |
2019 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
We previously showed that FKBP4, an HSP90-associated co-chaperone, can elicit immune response as a tumor-specific antigen, and are overexpressed in breast cancer.
|
31660083 |
2019 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.
|
30827868 |
2019 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
Adopting a pathophysiological perspective, this systematic review aims to synthesize the evidence examining the association between Hsp70/Hsp90 expression and breast cancer prognosis, as well as prognosis-related clinicopathological indices.
|
29491085 |
2018 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
|
29437790 |
2018 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
In this study, the activity of the Hsp90 inhibitor NVP-AUY922 was assessed in HER2 overexpressing breast cancer cell lines, including two cell line models of acquired trastuzumab-resistance.
|
29396630 |
2018 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
While Tan IIA did not inhibit heat shock protein 90 (Hsp90), it synergistically enhanced the antitumor efficacy of the Hsp90 inhibitors 17-AAG and ganetespib in human breast cancer MCF-7 cells.
|
29416003 |
2018 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
We show that the sensitivity of breast cancer cell lines to Hsp90 inhibition is highly variable.
|
30138434 |
2018 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
Ultimately, our results support the application of ganetespib-mediated HSP90 inhibition as a promising therapeutic strategy for ErbB2<sup>+</sup> breast cancer.
|
29717218 |
2018 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
Hsp90, an important member of HSP family, has an important role in breast cancer.
|
28801701 |
2018 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
In the present study, we further demonstrated that 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), an inhibitor of Hsp90, could suppress the self-renewal of BCSCs by downregulating B lymphoma Mo-MLV insertion region 1 homolog (BMI1), a polycomb family member with oncogenic activity in breast cancer.
|
28914785 |
2017 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
A subset of DNA repair proteins such as Breast cancer gene 1 (BRCA1), BRCA2 and RecA homolog (RAD51) are client proteins of heat shock protein 90 (Hsp90).
|
28111726 |
2017 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
This work sets the stage for immediately using Hsp90 to improve outcomes for breast cancer patients without affecting traditional care pathways.
|
29235516 |
2017 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
Up-regulation of cathepsin S expression by HSP90 and 5-HT<sub>7</sub> receptor-dependent serotonin signaling correlates with triple negativity of human breast cancer.
|
27796714 |
2017 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
However, it's still unclear the applicability of anti-HSP90 and anti-HDAC6 strategies in precision treatment of breast cancer.
|
28529458 |
2017 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
HS131 could image invasive lobular breast cancer, a histologic subtype of breast cancer which is often undetectable by mammography.<b>Conclusions:</b> An HSP90-targeting nIR probe is sensitive and specific in imaging all molecular subtypes of murine and human breast cancer, with higher uptake in aggressive and highly metastatic clones.
|
28993342 |
2017 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
Kaplan-Meier survival curves indicated that OBR and HSP90 expression were associated with reduced overall survival in breast cancer patients (HR = 1.9/p = 0.022; HR = 2.2/p = 0.00017, respectively).
|
26556856 |
2016 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
Biomarker |
BEFREE |
Hsp90 can constitute as much as 5% of total protein in transformed cells and increased levels of heat-shock activation correlate with poor prognosis in breast cancer.
|
26916007 |
2016 |
|
HSP90AA1
|
Breast Carcinoma
|
0.400 |
AlteredExpression |
BEFREE |
Here we used D,L-lactic-co-glycolic acid-polyethylene glycol-17-dimethylaminoethylamino-17-demethoxy geldanamycin (PLGA-PEG-17DMAG) complexes and free 17-DMAG to inhibit the expression of HSP90 gene in the T47D breast cancer cell line.
|
27268613 |
2016 |